MRNA: Has Moderna Had its Day?
Moderna broke on the scene, claiming that one of its drugs in development may be an effective vaccine against COVID-19. Naturally, the manic market speculators took the share price and…
Moderna broke on the scene, claiming that one of its drugs in development may be an effective vaccine against COVID-19. Naturally, the manic market speculators took the share price and…
We are at such a strange time. The rioters' rage and the statutes tumble. At the same time, investors are drunk on optimism. This article is for registered members -…
After the fastest bear market drop in history, the S&P 500 rallied and now has a year-to-date total return of -4.7%. The year is not over, but in the context…
As brick-and-mortar chains teeter in the face of the pandemic, Amazon continues to gain ground. The retail juggernaut is valued at no less than $1.4 trillion—roughly four times what it was…
In traditional monetary theory, one should see price inflation if the supply of money and credit rises more rapidly than the production of goods and services. This situation is probably…
Back on June 7, we suggested investors take a look at Gilead. Gilead is a huge biopharma that is in the race for treatments for Covid-19. This article is for…
On 23-June-2020, we presented our opinion concerning the price of long term bonds as represented by TLT, the 20+ year T-Bond ETF. In that discussion, we suggested that bond prices…
Biglots made an exciting announcement on Friday, and that communication caught the investment world flat-footed. This article is for paid members - please login or subscribe for access.
The rails have been one of the surprising beneficiaries since the financial crisis. We say surprisingly because, in the 70, 80 & the 90s, the railroads have been poor financial…
Every day, we talk to the average person on the street, and they cannot understand why the stock market is moving higher while the average person's experience is not so…